Prolyl hydroxylase inhibitors and methods of use

Patent metadata

Field	Value
Publication number	US-RE47437-E
Application number	US-201815875495-A
Country	US
Kind code	E1
Filing date	Jan 19, 2018
Priority date	Jun 26, 2006
Publication date	Jun 18, 2019
Grant date	Jun 18, 2019

Abstract

The present disclosure relates to HIF-1α prolyl hydroxylase inhibitors, compositions which comprise the HIF-1α prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.

First claim

What is claimed is:

1. A compound having the formula:

2. A pharmaceutical composition comprising:
A) the compound according to claim 1 ; and
B) one or more pharmaceutically acceptable excipients.

3. A compound having the formula:

4. A pharmaceutical composition comprising:
A) the compound according to claim 3 ; and
B) one or more pharmaceutically acceptable excipients.

5. A compound having the formula:

wherein:
R 6 is hydrogen, methyl, or ethyl;
R 7a and R 7b are each independently:
i) hydrogen; or
ii) methyl.

6. The compound according to claim 5 , wherein the compound is:
{[5-(3-Chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid methyl ester;
{[5-(3-Chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid ethyl ester;
5-(3-Chlorophenyl)-N-(2-amino-2-oxoethyl)-3-hydroxylpyridin-2-yl amide;
5-(3-Chlorophenyl)-N-(2-methylamino-2-oxoethyl)-3-hydroxylpyridin-2-yl amide; and
5-(3-Chlorophenyl)-N-(2-dimethylamino-2-oxoethyl)-3-hydroxylpyridin-2-yl amide.

7. A pharmaceutical composition comprising:
A) one or more compounds according to claim 6 ; and
B) one or more pharmaceutically acceptable excipients.

8. The composition according to claim 7 , wherein the compound is:
{[5-(3-Chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid methyl ester; or
{[5-(3-Chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid ethyl ester.

Assignees

• Akebia Therapeutics Inc

Inventors

• Kawamoto Richard Masaru
• Wu Shengde
• Evdokimov Artem G
• Greis Kenneth D
• Boyer Angelique Sun
• Warshakoon Namal C

Classifications

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P7/06

  Antianaemics · CPC title

• A61P7/00

  Drugs for disorders of the blood or the extracellular fluid · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P31/18

  for HIV · CPC title